Data-driven analysis to identify prognostic immune-related biomarkers in BRAF mutated cutaneous melanoma microenvironment

被引:1
作者
Huang, Biao [1 ,2 ]
Su, Wenxing [1 ,2 ]
Yu, Daojiang [1 ,2 ,3 ]
机构
[1] Chengdu Med Coll, China Natl Nucl Corp Hosp 416, Dept Plast & Burn Surg, Affiliated Hosp 2, Chengdu, Peoples R China
[2] Chengdu Med Coll, Dept Clin Med, Chengdu, Peoples R China
[3] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
BRAF mutated melanoma; TCGA; immune cells; prognosis; microenvironment; COMPREHENSIVE ANALYSIS; MEK; INHIBITION; CANCER; SERVER; CELLS;
D O I
10.3389/fgene.2022.1081418
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Skin cutaneous melanoma is one of the deadly diseases, and more than 50% of the patients have BRAF gene mutations. Evidence suggests that oncogenic BRAF modulates the immune system's ability to recognize SKCM cells. Due to the complexity of the tumor microenvironment (TME) and a lack of a rational mechanistic basis, it is urgent to investigate the immune infiltration and identify prognostic biomarkers in BRAF mutated SKCM patients. Multiple methods including ESTIMATE algorithm, differential gene analysis, prognostic analysis and immune infiltration analysis were performed to investigate the tumor microenvironment. Based on the patient's immune score and stromal score, immune-related genes DEGs were identified. Functional analysis revealed that these genes were mainly enriched in biological processes such as immune response, defense response and positive regulation of immune system. Furthermore, we analyzed the immune infiltrating cell components of BRAF mutated patients and revealed 4 hub genes associated with overall survival time. Several cells (Monocyte, Macrophage and Gamma delta cells) have been found to be significantly decreased in immune-high BRAF mutated SKCM group. While CD4(+)T, CD8(+)T, CD4 naive, Tr1, Th2 and many T cell subsets were significantly increased in immune-high group. These immune cells and genes were closely related to each other. This study revealed that the dysregulation of immune function and immune cells may contribute to the poor outcomes of BRAF mutated patients. It is of great significance to our further understanding of the TME and immune dysfunction in BRAF mutated SKCM.
引用
收藏
页数:14
相关论文
共 48 条
  • [1] MHC-II neoantigens shape tumour immunity and response to immunotherapy
    Alspach, Elise
    Lussier, Danielle M.
    Miceli, Alexander P.
    Kizhvatov, Ilya
    DuPage, Michel
    Luoma, Adrienne M.
    Meng, Wei
    Lichti, Cheryl F.
    Esaulova, Ekaterina
    Vomund, Anthony N.
    Runci, Daniele
    Ward, Jeffrey P.
    Gubin, Matthew M.
    Medrano, Ruan F. V.
    Arthur, Cora D.
    White, J. Michael
    Sheehan, Kathleen C. F.
    Chen, Alex
    Wucherpfennig, Kai W.
    Jacks, Tyler
    Unanue, Emil R.
    Artyomov, Maxim N.
    Schreiber, Robert D.
    [J]. NATURE, 2019, 574 (7780) : 696 - +
  • [2] Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
    Ascierto, Paolo A.
    Capone, Mariaelena
    Grimaldi, Antonio M.
    Mallardo, Domenico
    Simeone, Ester
    Madonna, Gabriele
    Roder, Heinrich
    Meyer, Krista
    Asmellash, Senait
    Oliveira, Carlos
    Roder, Joanna
    Grigorieva, Julia
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [3] Immunological effects of BRAF plus MEK inhibition
    Ascierto, Paolo A.
    Dummer, Reinhard
    [J]. ONCOIMMUNOLOGY, 2018, 7 (09):
  • [4] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
    Ascierto, Paolo Antonio
    Ferrucci, Pier Francesco
    Fisher, Rosalie
    Del Vecchio, Michele
    Atkinson, Victoria
    Schmidt, Henrik
    Schachter, Jacob
    Queirolo, Paola
    Long, Georgina V.
    Di Giacomo, Anna Maria
    Svane, Inge Marie
    Lotem, Michal
    Bar-Sela, Gil
    Couture, Felix
    Mookerjee, Bijoyesh
    Ghori, Razi
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Ribas, Antoni
    [J]. NATURE MEDICINE, 2019, 25 (06) : 941 - +
  • [5] Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Huang, Alex C.
    Sullivan, Brendan
    Richman, Lee P.
    Torigian, Drew A.
    George, Sangeeth M.
    Stelekati, Erietta
    Chen, Fang
    Melenhorst, J. Joseph
    Lacey, Simon F.
    Xu, Xiaowei
    Wherry, E. John
    Gangadhar, Tara C.
    Amaravadi, Ravi K.
    Schuchter, Lynn M.
    Vonderheide, Robert H.
    [J]. ONCOIMMUNOLOGY, 2018, 7 (10):
  • [6] NCBI GEO: archive for functional genomics data sets-update
    Barrett, Tanya
    Wilhite, Stephen E.
    Ledoux, Pierre
    Evangelista, Carlos
    Kim, Irene F.
    Tomashevsky, Maxim
    Marshall, Kimberly A.
    Phillippy, Katherine H.
    Sherman, Patti M.
    Holko, Michelle
    Yefanov, Andrey
    Lee, Hyeseung
    Zhang, Naigong
    Robertson, Cynthia L.
    Serova, Nadezhda
    Davis, Sean
    Soboleva, Alexandra
    [J]. NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D991 - D995
  • [7] Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
    Boni, Andrea
    Cogdill, Alexandria P.
    Dang, Ping
    Udayakumar, Durga
    Njauw, Ching-Ni Jenny
    Sloss, Callum M.
    Ferrone, Cristina R.
    Flaherty, Keith T.
    Lawrence, Donald P.
    Fisher, David E.
    Tsao, Hensin
    Wargo, Jennifer A.
    [J]. CANCER RESEARCH, 2010, 70 (13) : 5213 - 5219
  • [8] CD4+ T cell help in cancer immunology and immunotherapy
    Borst, Jannie
    Ahrends, Tomasz
    Babala, Nikolina
    Melief, Cornelis J. M.
    Kastenmueller, Wolfgang
    [J]. NATURE REVIEWS IMMUNOLOGY, 2018, 18 (10) : 635 - 647
  • [9] Acidic microenvironment plays a key role in human melanoma progression through a sustained exosome mediated transfer of clinically relevant metastatic molecules
    Boussadia, Zaira
    Lamberti, Jessica
    Mattei, Fabrizio
    Pizzi, Elisabetta
    Puglisi, Rossella
    Zanetti, Cristiana
    Pasquini, Luca
    Fratini, Federica
    Fantozzi, Luca
    Felicetti, Federica
    Fecchi, Katia
    Raggi, Carla
    Sanchez, Massimo
    D'Atri, Stefania
    Care, Alessandra
    Sargiacomo, Massimo
    Parolini, Isabella
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [10] Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
    Cabanillas, Maria E.
    Dadu, Ramona
    Iyer, Pryianka
    Wanland, Kacey B.
    Busaidy, Naifa L.
    Ying, Anita
    Gule-Monroe, Maria
    Wang, Jennifer R.
    Zafereo, Mark
    Hofmann, Marie-Claude
    [J]. THYROID, 2020, 30 (09) : 1288 - 1296